[{"address1": "Times Square Tower", "address2": "Suite 2503 7 Times Square", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 47, "title": "Founder, President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": 921985, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.55, "open": 1.21, "dayLow": 0.98, "dayHigh": 1.22, "regularMarketPreviousClose": 1.55, "regularMarketOpen": 1.21, "regularMarketDayLow": 0.98, "regularMarketDayHigh": 1.22, "beta": 2.354, "forwardPE": -1.2643678, "volume": 7236559, "regularMarketVolume": 7236559, "averageVolume": 1290367, "averageVolume10days": 1927390, "averageDailyVolume10Day": 1927390, "bid": 1.3, "ask": 1.38, "bidSize": 1000, "askSize": 3100, "marketCap": 47835812, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 1.91, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 0.8024, "twoHundredDayAverage": 1.22945, "currency": "USD", "enterpriseValue": 31943484, "floatShares": 31578118, "sharesOutstanding": 43487100, "sharesShort": 4513118, "sharesShortPriorMonth": 3116149, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.1038, "heldPercentInsiders": 0.00735, "heldPercentInstitutions": 0.15283, "shortRatio": 4.05, "shortPercentOfFloat": 0.1039, "impliedSharesOutstanding": 62463200, "bookValue": -0.135, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -38325000, "trailingEps": -1.52, "forwardEps": -0.87, "lastSplitFactor": "1:50", "lastSplitDate": 1573171200, "52WeekChange": -0.140625, "SandP52WeekChange": 0.29495108, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLS", "underlyingSymbol": "SLS", "shortName": "SELLAS Life Sciences Group, Inc", "longName": "SELLAS Life Sciences Group, Inc.", "firstTradeDateEpochUtc": 1205328600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d5f0c150-9f89-3f17-8497-1832af4e7670", "messageBoardId": "finmb_262231850", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.1, "targetHighPrice": 9.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.83, "targetMedianPrice": 7.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 3969000, "totalCashPerShare": 0.124, "totalDebt": 644000, "quickRatio": 0.338, "currentRatio": 0.443, "returnOnAssets": -1.43522, "returnOnEquity": -8.74002, "freeCashflow": -28823250, "operatingCashflow": -31737000, "financialCurrency": "USD", "trailingPegRatio": null}]